<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346827</url>
  </required_header>
  <id_info>
    <org_study_id>20102D05</org_study_id>
    <nct_id>NCT00346827</nct_id>
  </id_info>
  <brief_title>Apomorphine Nasal Powder in the Treatment of Parkinson's Disease &quot;Off&quot; Periods.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Britannia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Britannia Pharmaceuticals Ltd.</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in
      subjects with Parkinson's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3-week, double-blind, placebo-controlled, 3 Ã— crossover efficacy phase followed by 12 week open label phase, followed by 36 week open continuation phase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <enrollment type="Actual">36</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apomorphine Nasal Powder</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one
             documented &quot;off&quot; period per day

        Exclusion Criteria:

          -  hypersensitivity to apomorphine; participation in a clinical trial in the last 12
             weeks; pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Weiser, MB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swansea Hospital, Swansea, Wales</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

